# 510K SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92

The assigned 510(k) number is:

# COMPANY/CONTACT PERSON

Seradyn, Inc   
7998 Georgetown Road, Suite 1000   
Indianapolis, IN 46268

Establishment registration No: 1836010

Jack Rogers Manager of Regulatory Affairs Telephone: (317) 610-3823 Fax: (317) 610-0018

# DATE PREPARED

March 5, 2007

# DEVICE NAME

Trade Name: Seradyn QMS® Topiramate Common Name: Homogeneous Particle-Enhanced Turbidimetric Immunoassay Device Classification: 21 CFR 862.3660; Phenobarbital Test System; Class I

# INTENDED USE

The Seradyn M Topiramate ssay isintended or the quantitative eterminationf topiramatenu serum or plasma on automated clinical chemistry analyzers.

The results obtained are used in the diagnosis and treatment of topiramate overdose and in monitoring

# LEGALLY MARKETED DEVICE TO WHICH EQUIVALENCY IS CLAIMED

Seradyn noluor® Trmatsy K970510

# DESCRIPTION OF DEVICE

The Seradyn QMS Topiramate assay is a homogeneous particle-enhanced turbidimetric immunoassay. The assay is based on competition between drug in the sample and drug coated onto a microparticle for anibody binding sitesof the topiramate antibody reagent.The topiramate-coatedmicroparticle reagent is rapidly agglutinated in the presence of the anti-topiramate antibody reagent and in the absence of any competing drug in the sample. The rate of absorbance change is measured photometrically. When a sample containing topiramate is added, the agglutination reaction is partially inhibited, slowing down the rate absorbance change. A concentration-dependent classicagglutination inhibition curve can beobtained with maximum rate of agglutination at the lowest topiramate concentration and the lowest agglutination rate at the highest topiramate concentration.

The assay consists of reagents R1: anti-topiramate polyclonal antibody and R2: topiramate-coated mcroarticles. six-level set of Seradyn Q® Topiramate Calibrators is used to calibrate the assay. three-level set of Seradyn QMS® Topiramate Controls is used for quality control of the assay.

# COMPARISON OF TECHNOLOGICAL CHARACTERISTICS

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>DeviceSeradyn QMS® Topiramate</td><td rowspan=1 colspan=1>PredicateSeradyn Innofluor® Topiramate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The QMS Topiramate assay isintended for the quantitativedetermination of topiramate in humanserum or plasma on automatedclinical chemistry analyzers.</td><td rowspan=1 colspan=1>The Innofluor Topiramate assay isintended for the quantitativedetermination of total topiramate inserum or heparinized plasma byfluorescence polarization immunoassay(FPIA). The assay system is for use onthe TDx® or the TDxFLx® (TDx/TDxFLx)analyzer.</td></tr><tr><td rowspan=1 colspan=1>Indications forUse</td><td rowspan=1 colspan=1>The measurements obtained are usedin the diagnosis and treatment oftopiramate overdose and inmonitoring levels of topiramate to helpensure appropriate therapy.</td><td rowspan=1 colspan=1>The measurements obtained are usedin monitoring levels of topiramate toensure appropriate therapy.</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Homogeneous particle-enhancedturbidimetric immunoassay (particleagglutination) (PETIA)</td><td rowspan=1 colspan=1>Fluorescence PolarizationImmunoassay (FPIA)</td></tr><tr><td rowspan=1 colspan=1>ReagentComponents</td><td rowspan=1 colspan=1>Two (2) reagent system:Anti-topiramate Antibody Reagent(R1) in buffers containing proteinstabilizers with sodium azideTopiramate-coated MicroparticleReagent (R2) in buffer containingsurfactant as stabilizers with sodiumazide</td><td rowspan=1 colspan=1>Three (3) reagent system:Topiramate Antiserum (A) (Sheep) inbuffer with protein stabilizer and&lt;0.1% sodium azideTopiramate-fluorescein Tracer (T) inbuffer with surfactant, proteinstabilizer, and &lt;0.1% sodium azidePretreatment Buffer (B) withsurfactant</td></tr></table>

# SUMMARY OF CLINICAL TESTING

# Accuracy

Accuracy by Recovery was determined by diluting the high calibrator to12 concentrations across the assay range.The samples were analyzed in triplicate.

<table><tr><td rowspan=1 colspan=1>THEORETICALCONC.(μg/mL)</td><td rowspan=1 colspan=1>Rep 1</td><td rowspan=1 colspan=1>Rep 2</td><td rowspan=1 colspan=1>Rep 3</td><td rowspan=1 colspan=1>MeanResult</td><td rowspan=1 colspan=1>% RecoveryAcceptanceCriteria:100±10%</td></tr><tr><td rowspan=1 colspan=1>32.00</td><td rowspan=1 colspan=1>33.57</td><td rowspan=1 colspan=1>32.63</td><td rowspan=1 colspan=1>31.24</td><td rowspan=1 colspan=1>32.48</td><td rowspan=1 colspan=1>101.5%</td></tr><tr><td rowspan=1 colspan=1>24.00</td><td rowspan=1 colspan=1>24.26</td><td rowspan=1 colspan=1>24.41</td><td rowspan=1 colspan=1>24.83</td><td rowspan=1 colspan=1>24.50</td><td rowspan=1 colspan=1>102.1%</td></tr><tr><td rowspan=1 colspan=1>16.00</td><td rowspan=1 colspan=1>16.88</td><td rowspan=1 colspan=1>16.57</td><td rowspan=1 colspan=1>16.78</td><td rowspan=1 colspan=1>16.74</td><td rowspan=1 colspan=1>104.6%</td></tr><tr><td rowspan=1 colspan=1>8.00</td><td rowspan=1 colspan=1>8.27</td><td rowspan=1 colspan=1>8.30</td><td rowspan=1 colspan=1>8.48</td><td rowspan=1 colspan=1>8.35</td><td rowspan=1 colspan=1>104.4%</td></tr><tr><td rowspan=1 colspan=1>6.40</td><td rowspan=1 colspan=1>6.60</td><td rowspan=1 colspan=1>6.59</td><td rowspan=1 colspan=1>6.63</td><td rowspan=1 colspan=1>6.61</td><td rowspan=1 colspan=1>103.3%</td></tr><tr><td rowspan=1 colspan=1>3.20</td><td rowspan=1 colspan=1>3.45</td><td rowspan=1 colspan=1>3.41</td><td rowspan=1 colspan=1>3.54</td><td rowspan=1 colspan=1>3.47</td><td rowspan=1 colspan=1>108.4%</td></tr><tr><td rowspan=1 colspan=1>2.56</td><td rowspan=1 colspan=1>2.60</td><td rowspan=1 colspan=1>2.70</td><td rowspan=1 colspan=1>2.70</td><td rowspan=1 colspan=1>2.67</td><td rowspan=1 colspan=1>104.3%</td></tr><tr><td rowspan=1 colspan=1>1.92</td><td rowspan=1 colspan=1>2.16</td><td rowspan=1 colspan=1>2.03</td><td rowspan=1 colspan=1>2.15</td><td rowspan=1 colspan=1>2.11</td><td rowspan=1 colspan=1>109.9%</td></tr><tr><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>1.59</td><td rowspan=1 colspan=1>1.71</td><td rowspan=1 colspan=1>1.66</td><td rowspan=1 colspan=1>1.65</td><td rowspan=1 colspan=1>103.1%</td></tr><tr><td rowspan=1 colspan=1>1.28</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>1.33</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>1.33</td><td rowspan=1 colspan=1>103.9%</td></tr><tr><td rowspan=1 colspan=4>Mean Percent Recovery</td><td rowspan=1 colspan=1>Recovery</td><td rowspan=1 colspan=1>104.6 %</td></tr></table>

# Linearity

Linearity by Dilution was determined by a study based on the NCCLS guideline EP-A: Evaluation  the Linearity of Quantitative Measurement Procedures: A Statistical Approach.   

<table><tr><td rowspan=1 colspan=1>EstimatedValue(μg/mL)</td><td rowspan=1 colspan=1>DilutionFactor</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>1t OrderPredictedResult</td><td rowspan=1 colspan=1>2ndOrderPredictedResult</td><td rowspan=1 colspan=1>Percent DifferenceAcceptance Criteria:±10%</td></tr><tr><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0.8750</td><td rowspan=1 colspan=1>36.57</td><td rowspan=1 colspan=1>36.76</td><td rowspan=1 colspan=1>36.78</td><td rowspan=1 colspan=1>-0.04%</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0.7500</td><td rowspan=1 colspan=1>31.87</td><td rowspan=1 colspan=1>31.52</td><td rowspan=1 colspan=1>31.53</td><td rowspan=1 colspan=1>0.00%</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.5000</td><td rowspan=1 colspan=1>20.86</td><td rowspan=1 colspan=1>21.05</td><td rowspan=1 colspan=1>21.04</td><td rowspan=1 colspan=1>0.06%</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0.3750</td><td rowspan=1 colspan=1>15.89</td><td rowspan=1 colspan=1>15.82</td><td rowspan=1 colspan=1>15.80</td><td rowspan=1 colspan=1>0.09%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.2500</td><td rowspan=1 colspan=1>10.54</td><td rowspan=1 colspan=1>10.58</td><td rowspan=1 colspan=1>10.57</td><td rowspan=1 colspan=1>0.10%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.1250</td><td rowspan=1 colspan=1>5.28</td><td rowspan=1 colspan=1>5.35</td><td rowspan=1 colspan=1>5.34</td><td rowspan=1 colspan=1>0.06%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.0750</td><td rowspan=1 colspan=1>3.11</td><td rowspan=1 colspan=1>3.25</td><td rowspan=1 colspan=1>3.25</td><td rowspan=1 colspan=1>-0.02%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.0500</td><td rowspan=1 colspan=1>2.22</td><td rowspan=1 colspan=1>2.20</td><td rowspan=1 colspan=1>2.21</td><td rowspan=1 colspan=1>-0.13%</td></tr><tr><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.0375</td><td rowspan=1 colspan=1>1.68</td><td rowspan=1 colspan=1>1.68</td><td rowspan=1 colspan=1>1.68</td><td rowspan=1 colspan=1>-0.25%</td></tr></table>

# Sensitivity

The LOQ of the assay is defined as the lowest drug concentration for whic acceptable inter-assay precision is observed $( \leq 2 0 \%$ CV, with recovery $\pm 1 5 \%$

Based on the results, the package insert claim for LOQ will be $1 . 5 \mu g / m L$ .

# Assay Range

Bas on heAccuracy, Linearity, an Sensitivity LO) data, the package insert clai or he reorable range for the assay will be 1.5 to $3 2 . 0 ~ { \mu \ g / m L }$ .

# Method Comparison

A study was conducted according to NCCLS Guideline EP9-A2: Method Comparison and Bias Estimation Usigatint Samples  copacuracyecovery  topiate assayed $\mathsf { Q M S } ^ { \otimes }$ Topiramate assy  hat  the predicate ofluor Tomatassy.

Meanvalsr e Ior eneet we plot agais thos r e  metTeults using Passing - Bablok parameters are:

$N = 1 4 8$ E   
Slope $= 0 . 9 6 2$ EPY   
y-intercept $= 0 . 2 2 8$   
$R ^ { 2 } = 0 . 9 8 6$

Results show excellent correlation between the two assays.

# Precision

rion udy s peosiheatioal Coite or Clinical aboratoy Standar CCL guideline EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods.   

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>BETWEEN DAY</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean(μg/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.94</td><td rowspan=1 colspan=1>0.0813</td><td rowspan=1 colspan=1>2.77</td><td rowspan=1 colspan=1>0.0617</td><td rowspan=1 colspan=1>2.10</td><td rowspan=1 colspan=1>0.1238</td><td rowspan=1 colspan=1>4.22</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>10.14</td><td rowspan=1 colspan=1>0.1858</td><td rowspan=1 colspan=1>1.83</td><td rowspan=1 colspan=1>0.2371</td><td rowspan=1 colspan=1>2.34</td><td rowspan=1 colspan=1>0.3418</td><td rowspan=1 colspan=1>3.37</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>25.69</td><td rowspan=1 colspan=1>0.8295</td><td rowspan=1 colspan=1>3.23</td><td rowspan=1 colspan=1>0.7374</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>1.1405</td><td rowspan=1 colspan=1>4.44</td></tr></table>

Acceptance Criteria: $< 1 0 \%$ total CV

# Specificity

Metabolitestopirmateoun primarilyur patients beigdministered topiramate hapy. They are ot however seen t clinically nificant levels n plasma r serum. The topiramateasy p uliel oli

# Interferences

Interference studies were conducted using NCCLS Guideline EP7-A2: Interference Testing in Clinical Chemistry.

# 1) Endogenous Substances and HAMA

Clinically high concentrations of the following potential interferents were added to serum with known levels of topiramate (approximately 5 and $2 0 \ | | { \mathfrak { g } } / { \mathfrak { m } } { \mathfrak { L } } )$ . Each sample was assayed using the QMS Topiramate assay, along with a serum control of topiramate. All substances resultedin $\leq 1 0 \%$ error in detecting topiramate.

<table><tr><td rowspan=1 colspan=1>InterferingSubstance</td><td rowspan=1 colspan=1>InterferentConcentration</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>12 g/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>70 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>250 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Gamma-Globulin</td><td rowspan=1 colspan=1>12 g/dL</td></tr><tr><td rowspan=1 colspan=1>HAMA-1*</td><td rowspan=1 colspan=1>Normal Serum Levels</td></tr><tr><td rowspan=1 colspan=1>HAMA-2*</td><td rowspan=1 colspan=1>Normal Serum Levels</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>185.5 USP/mL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>500 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>825 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>30 mg/dL</td></tr></table>

\* Human anti-mouse antibodies

# Common Co-Administered Drugs

Studies were conducted to examine if any of the commonly administered compounds have any effect on the recovery of topiramate concentration. A high concentration of each compound was spiked into normal human serum with known levels of topiramate (approximately 5 and 20 ug/mL ) and assayed along with a serum control of topiramate.All compound resulted in $\leq 1 0 \%$ error in detecting topiramate.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>CompoundConcentration(μg/mL)</td><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>CompoundConcentration(μg/mL)</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>Lamotrigine</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>Acetazolamide</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>Levetiracetam</td><td rowspan=1 colspan=1>124</td></tr><tr><td rowspan=1 colspan=1>Alprazolam</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>Methysergide</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>Amitriptyline</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>Metoprolol</td><td rowspan=1 colspan=1>5.25</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>Nadolol</td><td rowspan=1 colspan=1>121</td></tr><tr><td rowspan=1 colspan=1>Atenolol</td><td rowspan=1 colspan=1>10.33</td><td rowspan=1 colspan=1>Naproxen</td><td rowspan=1 colspan=1>509</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>Nimodipine</td><td rowspan=1 colspan=1>75</td></tr><tr><td rowspan=1 colspan=1>Carbamazepine</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>Nortriptyline</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>Chlorthalidone</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>Phenelzine</td><td rowspan=1 colspan=1>14.38</td></tr><tr><td rowspan=1 colspan=1>Clonazepam</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>Phenobarbital</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Clorazepate</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>Primidone</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Diazepam</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>Protriptyline</td><td rowspan=1 colspan=1>1.03</td></tr><tr><td rowspan=1 colspan=1>Dichlorphenamide</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>Salicylic Acid</td><td rowspan=1 colspan=1>598</td></tr><tr><td rowspan=1 colspan=1>Ethosuxamide</td><td rowspan=1 colspan=1>252</td><td rowspan=1 colspan=1>Sulfanilamide</td><td rowspan=1 colspan=1>1500</td></tr><tr><td rowspan=1 colspan=1>Famotidine</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>Tolbutamide</td><td rowspan=1 colspan=1>642</td></tr><tr><td rowspan=1 colspan=1>Felbamate</td><td rowspan=1 colspan=1>243.33</td><td rowspan=1 colspan=1>Valproic Acid</td><td rowspan=1 colspan=1>100.67</td></tr><tr><td rowspan=1 colspan=1>Flurazepam</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>Verapamil</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Furosemide</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>Viagabatrin</td><td rowspan=1 colspan=1>112</td></tr><tr><td rowspan=1 colspan=1>Gabapentin</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>Zonisamide</td><td rowspan=1 colspan=1>122</td></tr><tr><td rowspan=1 colspan=1>Hydrochlororthiazide</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

Drugs tested that that may cross react with $> 1 0 \%$ error:

Ibuprofen • Phenytoin Tiagabine

# Anticoagulants

Studies were conducted to determine the performance characteristics of the assay for both serum and plasma samples containing topiramate.

The results indicatethat there iso significant difference betwen the ecoveryof topiramate in serum or plasma. The collection tubes evaluated show no adverse effects on the recovery of topiramate, within the experimental error for the spiking study.

A claim for assay application to both serum and plasma samples is thus supported.

# On-Board Stability

# Calibration Curve stability

Calibration curve stability of a period of 27 days is supported by the data.

# Reagent On-Board Stability

A 60 day on-board reagent stability claim is supported by the data.

# CONCLUSION

As summarized above, the Seradyn $\mathsf { Q M S } ^ { \mathfrak { G } }$ Topiramate assay is substantially equivalent to the Seradyn Innoluor® Topiramate assay.Substantial equivalence has been demonstrated through performance testing to verify that the device functions as intended and that design specifications have been satisfied.

Seradyn, Inc.   
c/o Mr. Jack Rogers   
Manager of Regulatory Affairs   
7998 Georgetown Road, Suite 1000 Indianapolis, IN 46268-5620

Re: k070645 Trade/Device Name: Seradyn QMS $^ \mathrm { \textregistered }$ Topiramate Regulation Number: 21 CFR 862.3660 Regulation Name: Phenobarbital test system. Regulatory Class: Class II Product Code: NWM Dated: March 05, 2007 Received: March 08, 2007

Dear Mr. Rogers:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class I (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M.Coopes, M.S. D.V.M. Jean M. Cooper, M.S., D.V.M.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k Numbe (f: 070045

Device Name: Seradyn QMS® Topiramate

# Indications for Use:

The Seradyn QMs® Topiramate assay is intended for the quantitative determination of topiramate in human serum or plasma on automated clinical chemistry analyzers.

The results obtained are used in the diagnosis and treatment of topiramate overdose and in monitoring levels of topiramate to help ensure appropriate therapy.

Concurrence of CDRH, Office of In Vitro Diagnostic-Devices (OIVD) Livision\$ign-Off Office of Yn Vitro Diagnostic Device Evaluation and Safety K070645 Page 1 of _